MNMD
Mind Medicine
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 0
stock price surged significantly
consensus rating "Buy"
Upward Gap
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MNMD
Mind Medicine (Mindmed) Inc.
A clinical stage biopharmaceutical company developing novel products to treat brain health disorders
One World Trade Center, Suite 8500, New York, New York 10007
--
Mind Medicine (MindMed) Inc., incorporated in Canada. They are a clinical-stage neurodrug development company that develops psychedelic-based drug candidates through rigorous scientific and clinical trials. Their mission is to discover, develop and deploy psychedelic-inspired drugs and therapies to treat psychiatry, neurology, addiction, pain, and potentially other disorders such as anxiety, substance abuse and withdrawal, and adult attention deficit disorder.
Company Financials
EPS
MNMD has released its 2024 Q4 earnings. EPS was reported at -0.41, versus the expected -0.28, missing expectations. The chart below visualizes how MNMD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available